All Oncology News

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Gurbakhash Kaur, MD, discusses the exploration of CELMoDs in multiple myeloma care and how they may affect the treatment paradigm.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

The bispecific ADC iza-bren elicited PFS and OS benefits compared with chemotherapy in pretreated, unresectable, locally advanced or metastatic TNBC.

Keck Medicine of USC researchers found a potential way to break the blood-brain barrier to improve immune checkpoint inhibitor efficacy in recurrent, high-grade astrocytoma.

Obrixtamig plus platinum chemo showed a 72% response rate and manageable safety in frontline DLL3-positive NEC in the phase 1 DAREON-7 trial.

Richard D. Kim, MD, discusses how positive results from PODIUM-303 exemplify and support the shift towards chemoimmunotherapy regimens in frontline SCAC.

A large transcriptomic analysis identified actionable gene fusions in 9% of glioblastomas, defining a targetable molecular subset.

Mario Sznol, MD, discusses adjuvant vs neoadjuvant immunotherapy in melanoma and highlights emerging vaccines, cell therapies, and T-cell engagers.

Encorafenib plus cetuximab and fluorouracil-based chemotherapy has received traditional FDA approval for BRAF V600E–mutant metastatic colorectal cancer.

Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US.

R. Lor Randall, MD, FACS, discusses a report on factors predicting local recurrence in nonmetastatic Ewing sarcoma from the phase 3 AEWS1031 trial.

Ashkan Emadi, MD, PhD, discusses how subcutaneous blinatumomab may represent a treatment approach in mixed phenotype acute leukemia.

Novel pembrolizumab-based combination regimens showed similar efficacy to the reference regimen in first-line ccRCC.

An analysis showed the manufacturing and distribution of Orca-T was consistent for patients with hematologic malignancies.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Huntsman Cancer Institute will soon become the first academic medical center in the US to manufacture a new prostate cancer imaging drug.

Sophia O’Brien, MD, discusses the role of nuclear medicine in lobular breast cancer diagnosis and staging, as well as use criteria for FES-PET/CT.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Data from the phase 2 SWOG S1512 trial showed a high pCR and durable survival outcomes with neoadjuvant pembrolizumab in resectable desmoplastic melanoma.

Five-year data from CheckMate 274 continued to show a durable DFS benefit with adjuvant nivolumab in high-risk MIUC.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

The new facility doubles Sylvester’s research footprint, breaking down barriers between scientific research and patient care.

Will the FDA approve giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy?

Subcutaneous amivantamab monotherapy received breakthrough therapy designation from the FDA for recurrent or metastatic, HPV-unrelated HNSCC.

Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS.

Martha Welman, MD, discusses the value of personalized patient relationships over technology, especially for populations with limited access to resources.